Search Results - "Rodriguez-Vida A"

ZODA Pharmacy Franchising Business Partnership a Proposed Action Plan.

Authors: Rodriguez, Vida Dulce E. Espiritu, Melchor

Source: Psychology & Education: A Multidisciplinary Journal. 2025, Vol. 33 Issue 3, p281-300. 20p.

Subject Terms: Business success, Franchisor-franchisee relationships, Food industry, Business partnerships, Business models

Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first‐line metastatic renal carcinoma (SUNRISES study).

Authors: Rodriguez‐Vida, Alejo Bamias, Aristotelis Esteban, Emilio et al.

Source: BJU International. Nov2020, Vol. 126 Issue 5, p559-567. 9p.

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma.

Authors: Stawiski, Konrad Perera‐Bel, Júlia Rodriguez‐Vida, Alejo et al.

Source: Molecular Oncology. Jun2026, p1. 16p. 5 Illustrations.

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.

Authors: Rodriguez-Vida, Alejo Maroto, Pablo Font, Albert et al.

Source: British Journal of Cancer. Jan2023, Vol. 128 Issue 1, p21-29. 9p.

Complexity of FGFR signalling in metastatic urothelial cancer.

Authors: Rodriguez-Vida, Alejo Saggese, Matilde Hughes, Simon et al.

Source: Journal of Hematology & Oncology. 10/24/2015, Vol. 8, p1-8. 8p.

Is there an antiandrogen withdrawal syndrome with enzalutamide?

Authors: Rodriguez‐Vida, Alejo Bianchini, Diletta Van Hemelrijck, Mieke et al.

Source: BJU International. Mar2015, Vol. 115 Issue 3, p373-380. 8p.

Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.

Authors: Rodriguez-Vida, Alejo Rodríguez-Alonso, Andrés Useros-Rodríguez, Eduardo et al.

Source: Clinical Genitourinary Cancer. Apr2022, Vol. 20 Issue 2, p197.e1-197.e10. 10p.

Management of fatigue and anaemia in men treated with androgen deprivation therapy.

Authors: RODRIGUEZ-VIDA, ALEJO CHOWDHURY, SUBHRA CHOWDHURY, SIMON

Source: Trends in Urology & Men's Health. May/Jun2014, Vol. 5 Issue 3, p25-28. 4p.

Diagnosis and management of testicular cancers.

Authors: Rodriguez-Vida, Alejo Chowdhury, Simon

Source: Trends in Urology & Men's Health. Sep2013, Vol. 4 Issue 5, p25-30. 6p.

Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients.

Authors: Sánchez, Julián Córdoba Picola, Natalia Rodriguez‐Vida, Alejo et al.

Source: Cancer Medicine. Dec2023, Vol. 12 Issue 24, p21969-21977. 9p.

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.

Authors: Boll, Lilian Marie Perera-Bel, Júlia Rodriguez-Vida, Alejo et al.

Source: Scientific Reports. 11/20/2023, Vol. 13 Issue 1, p1-14. 14p.

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.

Authors: Garcia de Herreros, Marta Jiménez, Natalia Padrosa, Joan et al.

Source: International Journal of Molecular Sciences. Jul2025, Vol. 26 Issue 13, p6244. 20p.

Mammalian target of rapamycin ( mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?

Authors: Rodriguez‐Vida, Alejo Chau, Noan‐Minh Chowdhury, Simon

Source: BJU International. Mar2014, Vol. 113 Issue 3, p350-351. 2p.

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

Authors: Gillessen, S. Gallardo, E. Choudhury, A. et al.

Source: Annals of Oncology. May2026, Vol. 37 Issue 5, p736-742. 7p.

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Authors: Vulsteke, C. Adra, N. Danchaivijitr, P. et al.

Source: New England Journal of Medicine. 4/2/2026, Vol. 394 Issue 13, p1257-1269. 13p.

631P Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study.

Authors: Rodriguez-Vida, A. Maroto Rey, J.P. Font Pous, A. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS665-S665. 1p.

PT127 - ATLAS: A phase 2, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma.

Authors: Rodriguez-Vida, A. Feyerabend, S. Loriot, Y. et al.

Source: European Urology Supplements. Mar2019, Vol. 18 Issue 1, pe1838-e1839. 2p.

199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis.

Authors: Szabados, B.E. Rodriguez-Vida, A. Duran, I. et al.

Source: Annals of Oncology. 2020 Supplement 6, Vol. 31, pS1319-S1319. 1p.

Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Authors: Robbrecht, Debbie Grob, Jean‐Jacques Bechter, Oliver et al.

Source: CTS: Clinical & Translational Science. Feb2024, Vol. 17 Issue 2, p1-11. 11p.

Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.

Authors: del Carpio, Luis P. Algarra, María Asunción Sabaté‐Llobera, Aida et al.

Source: Cancer Medicine. Jul2023, Vol. 12 Issue 13, p14062-14071. 10p.